Metabolon Biotech brings new Metabolome Platform

Metabolon, a precision medicine firm based in Research Triangle Park, has announced a new platform and tool to aid in the visualization of the metabolome. The whole set of small-molecule compounds identified within a biological sample is referred to as the metabolome. The Microbiome SmartPanel from Metabolon “demystifies” the gut microbiome by focusing on biologically relevant microbial and host-derived metabolites, as well as xenobiotic compounds, to reveal “deep insight” into microbiome function and its impact on host health, according to the business.

Meanwhile, its patented Heliogram visualization tool allows users to quickly link to the impact of therapeutic interventions on the host microbiota by exploring 13 microbiome pathways. “Metabolomics is an under-appreciated biological resource,” said Metabolon chief scientific officer, Rangaprasad (Ranga) Sarangarajan, Ph.D. It has the potential to make a significant contribution to the evolution of healthcare system technology because the findings impact practically every element of health, illness treatment, and health outcomes.

Metabolon, founded in 2000, specializes in metabolomics, which is the large-scale study of tiny compounds known as metabolites within cells, biofluids, tissues, or organisms. In the following months, the company aims to launch more SmartPanel solutions, according to the company. Furthermore, the company is developing unique methods for several focused assays that may be validated up to GCP criteria if necessary.

This is the first in a long line of dynamic and simple-to-understand metabolomics systems. We believe that by making metabolomics solutions more available to the general public, more drug developers will exploit the power of metabolomics to develop innovative therapeutics that will improve patient care. Metabolon completed a fresh round of funding in September 2020, raising $72 million in debt and equity.